Week of May 28, 2012: Astra Zeneca, GlaxoSmithKline Enter into Antibiotics Pact; Takeda to Acquire Multilab; and More - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Week of May 28, 2012: Astra Zeneca, GlaxoSmithKline Enter into Antibiotics Pact; Takeda to Acquire Multilab; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca and GlaxoSmithKline have announced a EUR 224-million ($280 million) public–private partnership funding to enable development of antibiotics for bacterial infections and drive information sharing. The objective of the proposed research program is to improve the scientific understanding of antibiotic resistance, design and implement efficient clinical trials, and take novel drug candidates through clinical development. The program is part of the European Commission’s Action Plan Against the Rising Threats from Antimicrobial Resistance, launched in November 2011. Read More

Sixty-two percent of life-science executives are struggling to cope with and use effectively the amount of information flooding their inboxes, according to a new report from the communications consulting firm Mediaplanet. The company is publishing the report and potential solutions in The Independent’s June 29, 2012, issue and also will be discussing its findings at the 10th Annual Pharmaceutical IT Congress, to be held in London Sept. 17–18, 2012. The company aims through its report to address several issues for the pharmaceutical industry, including diversification, externalization of R&D processes, operational simplification, and smooth access to external innovation.

Takeda Pharmaceutical has agreed to acquire Multilab, a pharmaceutical company that specializes in generic drugs and OTC products. Takeda expects that the transaction will be finalized by the end of the second quarter of fiscal year 2012. Under the agreement, Takeda Brazil will acquire Multilab in cash for Brazilian Real (BRL) 500 million ($250 million) upfront and up to BRL 40 million ($20 million) in additional future milestone payments to the owners of Multilab. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here